Cover Image
市場調查報告書

青年性黃斑部病變(斯特格氏病):開發平台分析

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257806
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
青年性黃斑部病變(斯特格氏病):開發平台分析 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 68 Pages
簡介

青年性黃斑部病變是兒童期·少年期發病的遺傳性眼科疾病,其最常見的形態被稱作為斯特格氏病(Stargardt disease)。斯特格氏病是先天性的平常染色體隱性遺傳症候群。主要的症狀·前兆有視野模糊,暗點呈現在視野中心部位上,無法從事讀書和精細的作業。主要的風險要素有動脈硬化症和高膽固醇症,抽煙,高血壓等。

本報告提供全球各國治療青年性黃斑部病變(斯特格氏病)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

青年性黃斑部病變概要

治療藥的開發

  • 青年性黃斑部病變開發中產品:概要
  • 青年性黃斑部病變開發中產品:比較分析

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Acucela Inc.
  • Alkeus Pharmaceuticals, Inc.
  • Ocata Therapeutics, Inc.
  • Sanofi

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ALK-001
  • echothiophate iodide
  • emixustat hydrochloride
  • Gene Therapy for Stargardt Disease
  • MA09-hRPE
  • SAR-422459
  • Small Molecule for Stargardt Disease
  • Stem Cell Therapy for Ophthalmic Disorders
  • VSM-20R

最新開發平台趨勢

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8396IDB

Summary

Global Markets Direct's, 'Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016', provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease)
  • The report reviews pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Juvenile Macular Degeneration (Stargardt Disease) therapeutics and enlists all their major and minor projects
  • The report assesses Juvenile Macular Degeneration (Stargardt Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Stargardt Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Juvenile Macular Degeneration (Stargardt Disease) Overview
  • Therapeutics Development
    • Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) - Overview
    • Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) - Comparative Analysis
  • Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics under Development by Companies
  • Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics under Investigation by Universities/Institutes
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Juvenile Macular Degeneration (Stargardt Disease) - Products under Development by Companies
  • Juvenile Macular Degeneration (Stargardt Disease) - Products under Investigation by Universities/Institutes
  • Juvenile Macular Degeneration (Stargardt Disease) - Companies Involved in Therapeutics Development
    • Acucela Inc.
    • Alkeus Pharmaceuticals, Inc.
    • Astellas Pharma Inc.
    • Copernicus Therapeutics, Inc.
    • Iris Pharma
    • Sanofi
  • Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALK-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • echothiophate iodide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emixustat hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy 1 to Activate ABCA4 for Stargardt Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MA09-hRPE - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Activate ABCA4 for Stargardt Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ramiprilat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-422459 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • soraprazan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Ophthalmic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects
  • Juvenile Macular Degeneration (Stargardt Disease) - Product Development Milestones
    • Featured News & Press Releases
      • May 26, 2015: Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases
      • May 04, 2015: European Medicines Agency Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease
      • Mar 31, 2015: Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
      • Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration
      • Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt's Macular Degeneration Phase 1 Trial in the United Kingdom
      • Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials
      • May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells
      • Apr 23, 2013: ACT Initiates Higher-Dosage Patient Treatment In European Phase I Study For Macular Degeneration
      • Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt's Macular Dystrophy
      • Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy
      • Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells
      • Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone
      • Dec 17, 2012: ACT Completes Higher-Dosage Cohort In European Clinical Trial For Stargardt's Macular Dystrophy Using Retinal Pigment Epithelial Cells
      • Nov 28, 2012: ACT Completes Higher-Dosage Cohort In Both US Clinical Trials Using Retinal Pigment Epithelial Cells
      • Nov 08, 2012: Advanced Cell Technology Announces Interim Data From Three Ongoing Macular Degeneration Trials
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H2 2016
  • Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Acucela Inc., H2 2016
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alkeus Pharmaceuticals, Inc., H2 2016
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Astellas Pharma Inc., H2 2016
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Copernicus Therapeutics, Inc., H2 2016
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Iris Pharma, H2 2016
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Sanofi, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H2 2016
  • Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top